Pattern Bioscience

The startup acknowledges the significant impact of drug-resistant bacterial infections, which claim over a million lives annually and incur billions of dollars in healthcare expenses globally. Recognizing the limitations of traditional diagnostic methods rooted in outdated technology, Pattern Bioscience aims to combat these challenges with its innovative approach.

Pattern Bioscience is developing the world's only culture-free, rapid diagnostic technology, designed to expedite pathogen identification and antibiotic susceptibility test results from days to mere hours. By leveraging single-cell analysis of microorganisms and machine learning tools, the company aims to deliver fast, clinically actionable information, ultimately enabling timely and effective treatment for patients. This, in turn, can save lives, mitigate side effects, and reduce healthcare costs.

The company recently secured a significant $28.70M Series C investment on April 27, 2023, with notable participation from Illumina Ventures, Antimicrobial resistance, Omnimed Capital, and Daleshaw. This substantial investment underscores the industry's confidence in Pattern Bioscience's innovative approach and its potential to drive positive change in the field of biotechnology and health care. Overall, Pattern Bioscience's groundbreaking technology and strategic investments position it as a promising contender in the fight against antimicrobial resistance and the advancement of global health.